Assembly Biosciences Repositions ABI-6250 as Multi-Indication Liver Drug With $100M Funding Boost

Assembly Biosciences expands ABI-6250 into Phase 2 basket study for PBC and PSC, backed by $100M equity offering. Stock rises 6.9% despite dilution.

Assembly Biosciences is reshaping its pipeline narrative, pivoting its lead candidate ABI-6250 from a focused hepatitis Delta therapy into a broader platform for cholestatic liver diseases. The move, announced alongside a $100 million equity offering, gives the clinical-stage biotech two distinct shots at value creation within the next twelve months.

The company plans to launch a Phase?2 basket study in the first quarter of 2027 targeting primary biliary cholangitis and primary sclerosing cholangitis — conditions where bile acid accumulation drives liver damage. That timeline follows a Phase?2 trial for chronic hepatitis Delta, which is slated to begin in the fourth quarter of 2026. The FDA has already been consulted via a pre-IND meeting, and while the official protocol is pending, management described the discussion as constructive.

ABI-6250 is an oral, small-molecule NTCP inhibitor. NTCP, a membrane protein on liver cells, serves both as a bile acid transporter and as an entry portal for the hepatitis Delta virus. Blocking it reduces bile acid uptake, a mechanism that could dial down inflammation in cholestatic diseases. Preclinical data, the pharmacological profile, and Phase?1a results showing a dose-dependent rise in plasma bile acids all underpin the expansion, according to the company.

To bankroll the broader development push, Assembly placed roughly 3.36?million shares at $26.50 each, along with pre-funded warrants covering up to 415,000 shares at $26.499 per warrant (exercise price $0.001). Gross proceeds come to about $100 million before expenses. The underwriters — Guggenheim Securities, UBS Investment Bank and Mizuho as joint bookrunners, with H.C. Wainwright as lead manager — hold a 30?day option for up to 566,040 additional shares at the offering price.

The investor syndicate includes Gilead Sciences, Commodore Capital, Farallon Capital Management and Columbia Threadneedle Investments, plus a large global fund and other healthcare specialists. The securities were issued under a shelf registration cleared by the SEC on March?27. Closing is scheduled for May?26.

Despite the dilutive mechanics — the offering represents roughly 27% of outstanding shares before any greenshoe exercise — the market took the news in stride. Shares closed Friday at $28.34, up 6.94%, after trading in a range of $27.64 to $31.89. Volume hit nearly 960,000 shares. The stock still sits about 26% below its 52-week high of $38.50 reached in November?2025, and the relative strength index of 28.6 points to oversold territory. Market capitalization stands at roughly $450 million.

Backing the equity raise, the balance sheet already appeared solid. As of March?31, 2026, cash and equivalents totaled $226.6?million — enough to fund operations into 2028. First-quarter revenue of $8.2?million came entirely from the Gilead collaboration, while R&D spending weighed in at $14.9?million and the net loss reached $9.1?million.

For investors, the central calculus is whether the expanded pipeline will outweigh the dilution. The next two catalysts — the hepatitis Delta Phase?2 start in Q4?2026 and the cholestatic basket study in early?2027 — should provide the answer. In the meantime, the offering’s unusual structure, with the placement price only modestly below the current share price, suggests that at least some large institutional buyers were willing to bet on the asset’s new breadth.